ClinicalTrials.gg
Not yet recruitingNCT07857889STORM-OFFUpdated Oct 8, 2026

Stellate Ganglion Neuromodulation for the Treatment of Electrical Storm

An interventional study of Stellate Ganglion Block Injection with Bupivicaine and Sham procedure control in Ventricular Tachycardia (V-Tach) Storm, sponsored by Population Health Research Institute. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Population Health Research Institute · Not applicable, Interventional, and Treatment

How we know

Updated Oct 8, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Tachycardia, Ventricular with a site in Canada — 17 open to participants now, 19 under way, 2 of them phase 3. Tachycardia, Ventricular · Canada.

Planned enrollment
11th of 39
300 · median 130
Started
2027
the only one that year
No phase
19 of 54
8 open now
Primary completion
2031-01
later than 18 of 18 live
Registered
54th of 54
by date

Among the 54 studies in Tachycardia, Ventricular with a site in Canada, this one is the 11th largest by planned enrollment of the 39 interventional ones that give a count, is the only one that started in 2027, is one of 19 with no phase, reaches primary completion later than 18 of the 18 other live ones, and was the 54th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

17 of the 54 studies in Tachycardia, Ventricular with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Tachycardia, Ventricular with a site in Canada, or all of them as a file.
02

Study summary

Ventricular tachycardia (VT) is a serious heart rhythm problem in which the heart beats very fast and in an abnormal way. These abnormal heart rhythms can be life-threatening. When a person has three or more episodes of VT within a 24-hour period, it is called a "VT storm." VT storm can be difficult to treat because some patients do not respond well to standard medications. Some studies suggest that a procedure called a stellate ganglion block (SGB) may help. An SGB involves injecting a local anesthetic near a group of nerves in the neck that help control signals between the brain and the heart. The procedure can be performed at the bedside using ultrasound guidance.

The purpose of this study is to find out whether SGB can delay or prevent the return of dangerous abnormal heart rhythms in patients with VT storm who are receiving care in an intensive care unit.

If a patient joins the study, they will be randomly assigned (by chance, like flipping a coin) to one of two groups. One group will receive a real stellate ganglion block. The other group will receive a sham procedure, in which a blunt needle will touch the skin but no injection will be given. Patients in the sham group who continue to experience VT may later receive the real procedure.

Participants will be followed until they leave the hospital or for 30 days after joining the study, whichever comes first. The study will take place at five hospitals across Ontario.

Read the detailed description

Stellate ganglion block (SGB) is currently a standard of care option for ventricular tachycardia (VT) storm. However, the evidence to support SBG is derived from non-randomized studies, thus there is a need to test this clinical procedure in an RCT with a sham procedure control. All aspects of the SGB intervention will occur in accordance with local clinical practice, with the exception of control arm participants receiving a sham injection as described below and in the protocol. The study case report forms will be used to collect information related to the local clinical assessments and procedures, as well as participant clinical status and outcomes, but will not dictate local clinical care.

Study summary:

Patients admitted to hospital with VT storm will be approached by study nurse or physician to gain consent for study participation. Study nurse or physician will use web-based randomization (ROME) to allocate participant to intervention or control arm. All participants who give consent will receive aseptic preparation and draping of the site of intervention, scanning with ultrasonography, and marking the site of needle entry with a plastic needle cap, in accordance with local practices. In both arms, a syringe with 10mL 0.5% bupivacaine will be ordered from local clinical supplies and prepared in accordance with institutional practices. The operator will document the intervention delivered in a dedicated case report form. All patients will undergo continuous ECG/telemetry monitoring and ICD interrogation (if applicable) per standard clinical care, for 72 hours following SGB.

SGB Arm:

SGB will be performed according to local practice. Local anesthesia will be delivered subcutaneously prior to the procedure. SGB typically occurs under dynamic ultrasound guidance. Once a landmark for the SGB is identified (e.g., the C6 anterior tubercle), 10 mL of 0.5% bupivacaine will be injected into the left side of the neck using a 22-25G nerve block spinal needle ventral to the longus colli muscle and beneath the prevertebral fascia. This will be a one-time injection. The efficacy of the block will be assessed qualitatively by the operator at the time of the procedure. Any unused bupivacaine will be discarded. The procedure typically takes approximately 20 minutes.

Sham procedure arm:

The sham-procedure will use the identical preparatory and procedural steps as described for the active arm. The procedure area will be screened off from the patient's view, and all equipment used in both active and sham arms will be identical and visible in the room. The duration of the sham procedure will match that of the active intervention, and communication during the procedure will be standardized for both arms. A small dressing will be applied to the site in both groups to further conceal which intervention was performed. Once the skin is draped and cleaned, control arm participants will have 1 mL of 0.5% bupivacaine injected, subcutaneously only. The operator will image the stellate ganglion using ultrasound but will not inject it. The operator will discard the unused bupivacaine to maintain blinding.

The study database will be hosted within PHRI's secure data centre, and eCRFs, including those pertaining to participant status and outcomes, will be completed by local site research assistants from available local medical records. No participant questionnaires or study-specific research tests or assessments are included in the protocol.

03

Conditions studied

  • Ventricular Tachycardia (V-Tach) Storm

Keywords

  • Ventricular tachycardia
  • Stellate ganglion block
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. ≥3 VT/VF episodes within 24 hours (including appropriate shock or antitachycardia pacing (ATP) terminated events) VT/VF episode definition: ventricular tachyarrhythmia episode ≥30 seconds in duration (VT or VF) requiring intervention regardless of duration, as captured on telemetry, or device intracardiac electrogram.
  3. \<12 hr since last VT/VF episode

Exclusion criteria

Exclusion Criteria:

  1. Standard clinical to nerve block (e.g., overlying site infection/allergy to the drug, cervical mass or history of neck cancer in the anticipated needle trajectory, others)
  2. VT storm secondary to underlying ion channelopathies (LQTS, SQTS, Brugada, CPVT, or CRDS)
  3. History of cardiac transplant or cardiac sympathetic denervation (CSD)
  4. count \<50,000 /µL
  5. VT/VF occurring in the setting of acute coronary syndrome prior to revascularization
  6. VT storm due to reversible causes (metabolic, drug mediated, etc.)
  7. Inability to obtain consent (from patient OR substitute decision maker)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Stellate Ganglion Block Arm

    SGB will be performed according to local practice. Local anesthesia will be delivered subcutaneously prior to the procedure. SGB should typically occurs under dynamic ultrasound guidance. Once a landmark for the SGB is identified (e.g., the C6 anterior tubercle), 10 mL of 0.5% bupivacaine will be injected into the left side of the neck using a 22-25G nerve block spinal needle ventral to the longus colli muscle and beneath the prevertebral fascia. This will be a one-time injection. The efficacy of the block will be assessed qualitatively by the operator at the time of the procedure. Any unused bupivacaine will be discarded. The procedure typically takes approximately 20 minutes.

    Procedure: Stellate Ganglion Block Injection with Bupivicaine

  • Sham comparator
    Sham Procedure Arm

    The sham-procedure will use the identical preparatory and procedure steps as described for the active arm. The duration of the sham procedure will match that of the active intervention, and communication during the procedure will be standardized for both arms. Once the skin is draped and cleaned, control arm participants will have 1 mL of 0.5% bupivacaine injected, subcutaneously only. The operator will discard the unused bupivacaine to maintain blinding.

    Other: Sham procedure control

Interventions

  • ProcedureStellate Ganglion Block Injection with Bupivicaine

    SGB will be performed according to local practice. Local anesthesia will be delivered subcutaneously prior to the procedure. SGB should typically occurs under dynamic ultrasound guidance. Once a landmark for the SGB is identified (e.g., the C6 anterior tubercle), 10 mL of 0.5% bupivacaine will be injected into the left side of the neck using a 22-25G nerve block spinal needle ventral to the longus colli muscle and beneath the prevertebral fascia. This will be a one-time injection. The efficacy of the block will be assessed qualitatively by the operator at the time of the procedure. Any unused bupivacaine will be discarded. The procedure typically takes approximately 20 minutes.

  • OtherSham procedure control

    The sham-procedure will use the identical preparatory and procedure steps as described for the active arm. The duration of the sham procedure will match that of the active intervention, and communication during the procedure will be standardized for both arms. Once the skin is draped and cleaned, control arm participants will have 1 mL of 0.5% bupivacaine injected, subcutaneously only. The operator will discard the unused bupivacaine to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Time to First Ventricular Tachycardia/Ventricular Fibrillation

    The primary outcome is the time to first recurrence of sustained VT/VF during the first 72 hours after randomization, following a 15-minute blanking period post intervention.

    Time frame: 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2031, 48 months later.

Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 48 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2031
CompletionEst.
Jul 2031
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Stellate Ganglion Neuromodulation for the Treatment of Electrical Storm: a Randomized Sham-controlled Trial
Oct 8, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 8, 2026
    Title Stellate Ganglion Neuromodulation for the Treatment of Electrical Storm: a Randomized Sham-controlled Trial
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857889
Collaborators
Hamilton Health Sciences Hospital
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Oct 8, 2026

Study contacts

Project Manager
Contact
STORM-OFF@phri.ca
905-521-2100

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion